Cancers (Mar 2022)
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
- Matteo Bauckneht,
- Sara Elena Rebuzzi,
- Marta Ponzano,
- Roberto Borea,
- Alessio Signori,
- Viviana Frantellizzi,
- Elisa Lodi Rizzini,
- Manlio Mascia,
- Valentina Lavelli,
- Alberto Miceli,
- Maria Silvia De Feo,
- Antonio Rosario Pisani,
- Susanna Nuvoli,
- Vincenzo Tripoli,
- Alessio Giuseppe Morganti,
- Paolo Mammucci,
- Salvatore Caponnetto,
- Guglielmo Mantica,
- Angelo Domenico Di Nicola,
- Carlo Villano,
- Luca Cindolo,
- Silvia Morbelli,
- Gianmario Sambuceti,
- Stefano Fanti,
- Renato Patrizio Costa,
- Angela Spanu,
- Giuseppe Rubini,
- Fabio Monari,
- Giuseppe De Vincentis,
- Giuseppe Fornarini
Affiliations
- Matteo Bauckneht
- Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
- Sara Elena Rebuzzi
- Medical Oncology, Ospedale San Paolo, 17100 Savona, Italy
- Marta Ponzano
- Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
- Roberto Borea
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Alessio Signori
- Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
- Viviana Frantellizzi
- Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00185 Rome, Italy
- Elisa Lodi Rizzini
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
- Manlio Mascia
- Unit of Nuclear Medicine, Spirito Santo Hospital, 65100 Pescara, Italy
- Valentina Lavelli
- Nuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
- Alberto Miceli
- Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
- Maria Silvia De Feo
- Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00185 Rome, Italy
- Antonio Rosario Pisani
- Nuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
- Susanna Nuvoli
- Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
- Vincenzo Tripoli
- Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, 90100 Palermo, Italy
- Alessio Giuseppe Morganti
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
- Paolo Mammucci
- Nuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
- Salvatore Caponnetto
- Medical Oncology Unit B, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy
- Guglielmo Mantica
- Department of Urology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Angelo Domenico Di Nicola
- Unit of Nuclear Medicine, Spirito Santo Hospital, 65100 Pescara, Italy
- Carlo Villano
- Unit of Nuclear Medicine, Spirito Santo Hospital, 65100 Pescara, Italy
- Luca Cindolo
- Department of Urology, Villa Stuart Private Hospital, 00185 Rome, Italy
- Silvia Morbelli
- Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
- Gianmario Sambuceti
- Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
- Stefano Fanti
- Department of Experimental, Diagnostic, and Specialty Medicine-DIMES, Alma Mater Studiorum Bologna University, 40138 Bologna, Italy
- Renato Patrizio Costa
- Unit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, 90100 Palermo, Italy
- Angela Spanu
- Unit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
- Giuseppe Rubini
- Nuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
- Fabio Monari
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
- Giuseppe De Vincentis
- Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00185 Rome, Italy
- Giuseppe Fornarini
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- DOI
- https://doi.org/10.3390/cancers14071744
- Journal volume & issue
-
Vol. 14,
no. 7
p. 1744
Abstract
The multicentric retrospective BIO-Ra study combined inflammatory indices from peripheral blood and clinical factors in a composite prognostic score for metastatic castration-resistant prostate cancer patients receiving Radium-223 (Ra-223). In the present study, we evaluated (i) the prognostic power of the BIO-Ra score in the framework of the restricted use of Ra-223 promoted by the European Medicines Agency in 2018; (ii) the treatment completion prediction of the BIO-Ra score. Four hundred ninety-four patients from the BIO-Ra cohort were divided into three risk classes according to the BIO-Ra score to predict the treatment completion rate (p p < 0.001) was observed. Despite this clinically relevant difference, BIO-Ra classes still predicted divergent treatment completion rates in the post-restriction subgroup (72%, 52.2%, and 46.3% of patients belonging to low-, intermediate-, and high-risk classes, respectively). Although the restricted use has increased patients at higher risk with unfavourable outcome after Ra-223 treatment, the BIO-Ra score maintains its prognostic value.
Keywords
- metastatic castration-resistant prostate cancer
- Radium-223
- inflammatory indices
- neutrophil-to-lymphocyte ratio
- clinical factors
- treatment completion
